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 1 Introduction 
1.1 Goal of the document 
According to Regulation (EC) No 258/97, in order to market a novel protein in the European Union 
(EU), its safety needs to be assessed prior to market introduction. Novel proteins are proteins which 
have not been used for human consumption to a significant degree within the EU before 15 May 1997. 
Therefore, any person, producer or importer who wishes to market such a novel protein in the EU 
must submit an application dossier to a competent authority (CA) for novel foods of an EU member 
state for an assessment of safety. Commission Recommendation 97/618/EC provides general 
guidelines on the administrative and scientific contents of an application dossier. Many companies who 
want to market novel food products struggle with making such an application dossier however. This 
document aims to assist in making an application dossier for novel food proteins. 
 
This document describes when a new protein intended to market for human consumption is considered 
to be a novel food protein (novel protein) and when it is not, when an application dossier for 
authorisation must be made and when, in general, an application dossier for notification might be 
sufficient. It describes in detail the items to be addressed in these application dossiers and gives 
references to guidance documents of CAs and provides examples. It also provides guidelines of what 
information for each item might consider being sufficient by CAs. However, for many items there are 
no clear-cut criteria. Furthermore, each application dossier for a novel protein will be different due to 
specific product related characteristics. Moreover, the opinion from member states’ CAs or European 
Food Safety Authority (EFSA) cannot be predicted. The information in this document can, therefore, 
only be regarded as a guideline. 
1.2 The goal of an application dossier for novel protein 
Why do you have to make an application dossier for a novel food? It is good to keep in mind that you 
are not making an application dossier just to comply with demands from the government. You are 
making an application dossier to convince anybody, from consumers, business-to-business 
customers and media to health authorities that the product you aim to market is safe when 
the product is consumed by humans in the form and to the extent as you describe in the 
dossier. You should tell a convincing story in the application dossier substantiating that your new 
protein is safe for human consumption. You need to put all information which is necessary to prove 
this in the application dossier, more than this is not needed. 
1.3 Application procedures for novel foods 
Before going into detail about the information needed in an application dossier in the next chapters, 
this paragraph provides, in short, information about the application procedures for novel foods.  
An applicant has to submit his request for placing a novel food product on the EU market to a CA for 
novel foods in one EU member1. Each EU member state has a CA for novel foods, which has the legal 
responsibility to execute Regulation (EC) No 258/97. The request to the first member state should 
contain an application dossier including all the necessary information, including copies of all studies 
carried out, and a summary. 
1 Application procedure is not unique for novel foods: comparable procedures are required for pesticides and veterinary 
medicines. 
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At the same time a copy of the request has to be sent by the applicant to the EC. The EC must 
forward the request, the name of the CA responsible for the initial safety assessment and the 
summary of the application dossier to the CAs of the other member states. The CA assesses the 
application dossier and makes an initial assessment report including a decision on whether an 
additional assessment is required or not. Some member states have a separate assessment body, 
which performs the assessments of application dossiers and advices the CA (Appendix I). The initial 
assessment report of the national CA is sent to the European Commission (EC). The EC forwards the 
initial assessment report to the CAs of all other member states for comments or reasoned objections. 
If no additional assessment was considered to be necessary by the first member state and no 
comments were made or objections were raised, the first member state informs the applicant that he 
is allowed to place the novel food product on the market. If an additional assessment was considered 
to be necessary or comments or objections were made, the application dossier is nowadays forwarded 
to EFSA for further assessment. In case of a positive opinion of EFSA, the EC drafts a proposal for 
authorisation of the novel food. If the Council and the European Parliament do not object to the 
proposal, the EC publishes the authorisation in the Official Journal of the European Union.  
 
For novel foods that are substantially equivalent to existing foods or food ingredients as regards their 
composition, nutritional value, metabolism, intended use and levels of undesirable substances, the 
applicant should notify the EC. Nowadays, most applicants first submit such a notification, by a 
notification dossier, to the CA of a member state to obtain an opinion of the CA on the equivalence 
status of the product. This opinion is then included in the notification dossier that is sent to the EC. 
The EC forwards the notification to the CAs of all member states.  
 
The procedures and organisations involved in the assessment of application dossiers submitted to the 
CA in the Netherlands are described in a decision tree developed by Wageningen UR which is available 
on the internet2,3. Although national CAs are different in the EU member states, the general 
procedures are similar. 
 
An applicant has to pay a fee to the CA in the member state where the application dossier is submitted 
for the initial assessment. The fee is set by the member state, and the height of the fee depends on 
the kind of application dossier: notification or authorisation. Fees differ between countries (see 
Appendix II for fees of some member states). Don’t let the choice for submission to which member 
state be guided by the height of the fee alone. Countries with a higher fee could have more experience 
in dealing with application dossiers and might be more willing to interact with the applicant during the 
making of an application dossier prior to submission. Such interaction could save money and time in 
making a correct application dossier, which could easily compensate the higher fee. 
 
CAs or their assessment bodies in some countries, like the Netherlands, the UK, and Finland, have 
much experience in dealing with novel food applications and have shown to be open to an exploratory 
discussion on request of the applicant about the novel food product before official submission of an 
application dossier for first assessment. Such exploratory discussions are often free of charge. 
 
  
2 Authorisation procedure: http://eiwitinnovaties.fbresearch.nl/page/decision-tree-authorisation-novel-food 
3 Notification procedure: http://eiwitinnovaties.fbresearch.nl/page/decision-tree-notification-novel-food 
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Regulation in progress 
Since 2008 the European Commission is working on a simpler, clearer and more efficient authorisation 
procedure. Recently the European Commission (18-12-2013) released a Draft Regulation on novel 
foods: Proposal COM (2013) 894 final4. This draft Regulation is not in force yet, and it probably will 
not enter into force before 2016.  
 
Under the draft Regulation, novel food would enter an authorisation procedure centralised at EU level: 
this may lead to a reduction of the authorisation procedure (18 months instead of 3 years in average 
currently). 
 
Authorisation will be generic, which will avoid the resubmission of new applications by other 
companies for the same novel food. Protection of innovation is covered by a ‘data protection’ regime, 
with the granting of an applicant linked authorisation for a maximum of 5 years. 
 
Furthermore, special provisions are made for food which has not been marketed in the EU but which 
has a history of safe use in non-EU countries. If a history of safe food use in a third country for at 
least 25 years has been demonstrated by the applicant, the food may be included in the Union list. 
Those foods should have been consumed in the third country as a part of the customary diet within a 
large part of the population of the country and be confirmed with compositional data. The history of 
safe food use should not include non-food uses or uses not related to normal diets. 
 
1.4 Reading guide 
Chapter 2 provides information and background for when a novel protein is not to be considered a 
novel food, in which case no application dossier has to be submitted to a CA. Chapter 3 provides 
information and background for making an application dossier for authorisation. Finally, chapter 4 
provides information and background for making an application dossier for notification for novel 
proteins considered to be substantially equivalent to an existing food protein that is already allowed on 
the EU market. 
 
In this document we refer to texts of other documents. We do not copy the texts of these documents; 
instead we provide links to the website where to find the documents in a footnote on the page. For 
examples of specific topics in an already assessed application dossier, we provide the link to the 
website where to find the application dossier with a reference to the chapter concerned in the 
application dossier. If we use a figure or a table from another document, a link to its source is 
provided in a note to the figure or table. 
  
4
 Proposal http://ec.europa.eu/food/food/biotechnology/novelfood/documents/novel-cloning_com2013-894_final_en.pdf 
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 2 Is the novel protein a novel food? 
2.1 When is a new protein not a novel food? 
According to Regulation (EC) No 258/975 a new protein is a novel food if it has not been used for 
human consumption to a significant degree within the EU before 15 May 1997. The deadline of 15 May 
1997 applies to all current member states, irrespective from the date of accession to the EU. To prove 
that a new protein is not a novel food, a person, producer or importer who aims to market it has to 
demonstrate ‘human consumption to a significant degree within the EU’. Only consumption in the EU is 
evidence; consumption outside the EU is no evidence for significant consumption within the scope of 
Regulation (EC) No 258/97. 
 
Figure 2.1 provides a decision tree for assessing human consumption to a significant degree. By 
following the questions in this decision tree and gathering the data to answer these, you can establish 
if the new protein is a novel food or not. If your new protein is exactly the same as a protein that is 
already on the EU market, and use of your protein will be the same, you need to prove that it is the 
same. Therefore, you need to specify the 1) full Latin name of the source organism (taxonomic name) 
and other names used in EU member states; 2) the parts of the source organism used before 15 May 
1997; 3) the form and/or concentration of the protein (fluid, extract etc.) which were used; and 4) the 
intake of the protein compared to intake of the new protein. Previous use of the protein in food 
supplements only is not considered to be sufficient as evidence for a history of consumption. Table 2.1 
provides a list of types of evidence of a history of human consumption you can use to substantiate 
history of consumption. The more concrete and detailed the information about sales and consumption 
in the EU, the better is the evidence. The document of the Belgian government ‘Tools to prove that a 
food or food ingredient is not a novel food (.PDF)’6 can also help to identify human consumption to a 
significant degree. In some member states the CA can be consulted to aid in this process of 
determining whether a protein is a novel food or not. 
If a protein was consumed to a significant degree before 15 May 1997 in the EU, no application dossier 
has to be submitted to a national CA for novel foods. However, a CA or other government body could 
ask a person, producer or importer to show that the protein in question is not a novel food within the 
scope of Regulation (EC) No 258/97. Therefore, it is advisable to collect the evidence on human 
consumption to a significant degree in a dossier before marketing, this dossier can be shown upon 
request of official authorities.  
 
  
5 http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:1997R0258:20090807:EN:PDF 
6 http://www.health.belgium.be/eportal/foodsafety/foodstuffs/novelfoods/index.htm?fodnlang=en 
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 Table 2.1 
Types of evidence of a history of human consumption of product in EU 
Type of Evidence  Examples of type of evidence Possible Weighting 
Comprehensive Sales Information Invoices etc., detailing sale of food, including 
evidence of large quantities of sale in the EU 
Very Good Evidence, if purpose (food use) 
is indicated 
Sales Information  Invoices etc., detailing sale of food  Good Evidence, if purpose (food use) is 
indicated 
Government Import/Export 
Information 
Official documents Supporting Evidence, if purpose (food 
use) is indicated 
Sales Information Catalogues, Sales Brochures Supporting Evidence, if purpose (food 
use) is indicated 
Listed in recognised 
catalogues/documents 
 Supporting Evidence 
Expert knowledge Personal Testimonies Supporting Evidence 
Supporting Information Magazine articles, Recipe Books etc. Supporting Evidence 
Other Please Specify  
Source: http://ec.europa.eu/food/food/biotechnology/novelfood/documents/substantial_equivalenc_en.pdf. 
 
 
 
Figure 2.1 Decision tree to identify whether a product is a novel food (source: 
http://ec.europa.eu/food/food/biotechnology/novelfood/documents/substantial_equivalenc_en.pdf). 
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Figure 2.1 shows a decision tree to identify whether no significant consumption in the EU before 15 
May 1997 can be established which means the product is a novel food. If more information is needed 
a novel food dossier has to be set up. 
2.2 What to do if the protein is a novel food: authorisation 
or notification? 
If for a protein no significant consumption in the EU before 15 May 1997 can be established, the 
person, producer, or importer who aims to market this protein, has to make an application dossier. 
The application dossier has to be submitted to a national CA for novel foods for assessment. In 
general, an application dossier for authorisation has to be made. Chapter 3 provides information, 
instructions, practical tips, and examples for application dossiers for authorisation (full application). If, 
however, substantial equivalence with an existing counterpart already allowed on the EU market can 
be established, an application dossier for notification can be sufficient. Chapter 4 provides information, 
instructions, tips, and examples for an application dossier for notification (the simplified procedure). 
Only after (1) the novel protein has been assessed to be safe; and (2) either the first member state 
informs you that you are allowed to place your product on the market; or (3) the EC has published the 
authorisation in the Official Journal of the European Union; or (4) has listed the notification on the DG 
SANCO website (http://ec.europa.eu/food/food/biotechnology/novelfood/index_en.htm), the protein 
can be placed on the EU market. 
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 3 Application dossier for authorisation 
If a new protein is a novel food within the scope of Regulation (EC) No 258/97, in most cases an 
application dossier for authorisation has to be made. This chapter provides information, instructions, 
tips, and examples for application dossiers for authorisation (full application). When substantial 
equivalence with an existing counterpart already allowed on the EU market can be established, an 
application dossier for notification can be sufficient. Chapter 4 provides information, instructions, tips, 
and examples for an application dossier for notification. According to Part II of Recommendation 
97/618/EC7, an application dossier for authorisation should contain the following six chapters: 
 
1. Administrative data. 
2. General description. 
3. Identification of essential information requirements. 
4. Consultation of structured schemes. 
5. Evaluation and conclusion by the applicant. 
 
 
1. Summary by the applicant 
The information needed in each of these chapters is explained in paragraphs 3.1 to 3.6. 
Previously approved applications dossiers for authorisation can be used as example when making an 
application dossier for a novel protein. Box 1 provides links to two of these application dossiers, 
namely for chia seeds and for Touchi extract of soybean. The examples concern the public parts of the 
application dossiers. More application dossiers for authorisation assessed in the UK can be found on 
the website8 of The Advisory Committee on Novel Foods and Processes (ACNFP) under ‘Full 
applications submitted via the UK’. 
 
 
3.1 Administrative data 
The administrative chapter should contain the following information: 
• Name, postal and email address, telephone, and fax of the applicant of the application dossier. 
• Name, postal and email address, telephone, and fax of the producer of the novel protein. 
• Name, postal and email address, telephone, and fax of the person responsible for the application 
dossier. 
• Date of the application. 
 
3.2 General description 
According to Chapter 4 of Recommendation 97/618/EC the applicant must, with a scientific 
justification, assign the novel protein to one of three classes/subclasses9: 
7 http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:1997:253:0001:0036:EN:PDF 
8 http://acnfp.food.gov.uk/assess/ 
9 Classes 3, 4 and 5 referred to genetically modified organisms and are no longer within the scope of the Regulation (EC) No 
258/97. 
Box 1: The public part of application dossiers for authorisation of Chia seeds and Touchi 
extract of soybean 
 
Chia seeds 
The application dossier for authorisation is available at 
http://www.food.gov.uk/multimedia/pdfs/applicdosschiacompany.pdf. 
 
Touchi extract of soybean 
The application dossier for authorisation is available at 
http://www.food.gov.uk/multimedia/pdfs/touchiapplication.pdf. 
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Class 1: Pure chemicals or simple mixtures from non-GM sources. This class comprises foods and 
food components that are single chemically defined substances or mixtures of these which 
are not obtained from plants, animals, or microorganisms that have been genetically 
modified. Two sub-classes can be identified: 
1.1 the source of the novel food has a history of food use in the EU; 
1.2 the source of the novel food has no history of food use in the EU. 
Class 2: Complex novel food from non-GM source. This class comprises complex novel food which are 
not, or are derived from sources which have not, been genetically modified. Intact plants, 
animals, and microorganisms used as foods as well as food components (e.g. complex 
carbohydrates, fats, proteins or those substances collectively described as dietary fibre) are 
included. Two sub-classes can be identified: 
2.1 the source of the novel food has a history of food use in the EU; 
2.2 the source of the novel food has no history of food use in the EU. 
Class 6: Foods produced using a novel process. This class comprises foods and food ingredients 
which have been subjected to a process not currently used in food production. Novel 
processes for food production may encompass, for example, new types of heat processing, 
non-thermal preservation methods, new processes to chill or freeze products, to dehydrate 
products, and the application of new processes catalyzed by enzymes. According to the 
scope of Regulation (EC) No 258/97, the resulting product is only considered to be a novel 
food, if the process results in changes in the chemical composition or structure of the food or 
food ingredient, which affect its nutritional value, metabolism, or level of undesirable 
substances. 
3.3 Identification of essential information requirements 
Based on the class/subclass allocation, the applicant can identify in table 3.1 (Table II from 
Recommendation 97/618/EC) what information is needed in the application dossier. 
 
 
Table 3.1 
Structured schemes for identification of the class and subclass of a novel protein. 
Structured scheme Class of novel protein 
1.1 1.2 2.1 2.2 6 
I. Specification of the novel protein xa x x x x 
II. Effect of the production process applied to the novel protein x x x x x 
III. History of the organism used as source of the novel protein x x x x x 
IX. Anticipated intake/extent of use of the novel protein x x x x x 
X. Information from previous human exposure to the novel protein or its source x  x  x 
XI. Nutritional information on the novel protein x x x x x 
XII. Microbiological information on the novel protein x x x x x 
XIII. Toxicological information on the novel protein x x x x x 
a x = The information mention in this structured scheme is needed in the dossier. 
Source: Table II from Recommendation 97/618/EC. 
So, there are hardly any differences in data requirements for the different protein classes. Even for item X. information from previous human 
exposure, applies that if a novel protein does have a history of food use outside the EU, it is recommended to include information on this in 
the dossier. 
 
3.4 Consultation of structured schemes 
The data needed to answer the questions in the structured schemes in Recommendation 97/618/EC 
form the main body of an application dossier for authorisation. The data needed for each structured 
scheme are explained in detail in the following paragraphs. 
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3.4.1 Specification of the novel protein 
Figure 3.1 (Scheme I of Recommendation 97/618/EC) refers to the specification of the source and the 
composition of the novel protein. Table 3.2 provides the questions in scheme I, and information and 
suggestions for answering each question. For the composition, all parameters relevant to characterise 
the product from a safety and nutritional point of view must be analysed. The information in the 
application dossier should be representative for the novel protein produced on a commercial scale. The 
taxon of the source of the novel protein must be specified as detailed as possible (e.g. class, order, 
family, genus, species, subspecies, variety, cultivar, etc.) 
 
 
Table 3.2 
Specification of the novel protein: composition, representativeness for commercial production and 
taxonomic identity 
Question from scheme I (Figure 3.1) Information and suggestions 
Depending on the derivation and composition of the 
Novel Food, is appropriate analytical information 
available on potentially toxic inherent constituents, 
external contaminants and nutrients? 
 
Use at least four different batches for compositional analyses. The 
batches must be representative for the product to be placed on the 
EU-market. 
Preferably, let analyses be performed by accredited laboratories. 
If possible, use official sampling methods and (criteria for) methods 
of analysis 
Indicate the method of analysis per parameter  
Provide data on composition like (note that not all parameters are 
applicable to all products): 
Appearance; 
Crude composition: moisture, total protein, total fat, ash, total 
carbohydrates, crude fibre; 
Amino acid profile, fatty acid profile; 
For isolated proteins: purity of the protein, solubility, pH 2% 
solution, amino acid composition, molecular mass, isoelectric point, 
absorption spectra, protease sensitivity, heat stability; 
Micronutrients: vitamins (A, B1, B2, B3, B5, B6, B8, B9, B12, C, D, 
E, K1), minerals (Ca, Mg, P, Na, K, Zn, Fe, Cu, Mn, Cl), other 
relevant substances; 
Inherent plant or animal toxins and/or antinutritional substances; 
Heavy metals (Cd, Pb, As, Hg, Ni), pesticide residues, mycotoxins, 
other contaminants (like dioxins, dioxin-like PCBs, PCBs, PAHs, etc); 
Substances used in processing (like solvents); 
Substances formed during processing; 
Microbiology: total bacteria (standard plate count), aerobic bacteria, 
Enterobacteriaceae, bacteria mentioned in Regulation (EC) 
2073/2005, yeasts and moulds. 
Add copies of full laboratory reports (appendix). 
Add copies of the accreditation certificate of the labs (appendix). 
Give specifications of each of the parameters mentioned (e.g. 
minimum, maximum, range, >, <). 
Compare results of compositional analysis with your specifications 
and if applicable with legal limits in products (Table 3.3). 
Is the information representative of the novel food 
when produced on a commercial scale? 
 
Provide compositional information from batches that are 
representative for the product to be placed on the EU market. 
State where and when the batches used in the analyses were 
produced. 
If necessary, perform studies to show compositional stability of 
product during storage. 
Is there an appropriate specification (including 
species, taxon, etc. for living organisms) to ensure 
that the novel food marketed is the same as that 
evaluated? 
Use the Latin name (scientific nomenclature) to uniquely identify the 
source of the novel protein. 
Provide the taxon minimally up to the level of species, sub-species 
and variety (for example a chicken is Gallus gallus domesticus). 
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Figure 3.1 Scheme I for specification of the novel food (NF) (Source: Recommendation 97/618/EC). 
 
Details on information and suggestions about questions in Scheme I for specification of the novel food 
The chemical, microbial and physical characteristics of the novel protein have to be specified. In 
general, four or more samples of the novel protein should be analysed to determine average level, 
standard deviation, and minimum and maximum levels of each of the compounds. The novel protein 
and its composition must be representative of the protein when produced at a commercial scale. The 
potential influence of the proposed production processes, transport, and storage during the entire 
proposed shelf life of the novel protein on the characteristics should be taken into account. If the 
length of the storage time is expected to vary significantly, storage studies may be necessary to 
investigate the stability of the novel protein until the maximum expected storage time. If the source of 
the novel protein is produced at different locations in the world, it may be necessary to analyse 
batches of the novel protein derived from sources from different locations in order to gain insight into 
the variation in the composition of the novel protein. The type of substances of the composition 
needed to be analysed, depends on the novel protein. Some guidelines for this are: 
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• Appearance, crude composition (moisture, total protein, total fat, ash, total carbohydrates, crude 
fibre), key micro-nutrients (vitamins A, B1, B2, B3, B5, B6, B8, B9, B12, C, D, E, K1, minerals Ca, 
Mg, P, Na, K, Zn, Fe, Cu, Mn, Cl, other relevant substances), anti-nutritional substances and 
inherent plant or animal toxins may have to be determined depending on (the source of) the novel 
food. Information on key nutrients, anti-nutrients and toxins characteristic for some specific crop 
plant species (such as sugar beet, soybean and maize) and the extent of natural variation of these 
substances are provided in OECD consensus documents10. 
• Information on the presence of micro-organism should be provided (like on total bacteria using a 
standard plate count, aerobic bacteria, Enterobacteriaceae, moulds and yeasts). The selection of 
micro-organisms sought for should be determined based on the characteristics of the product (and 
production process), and should include those bacteria, moulds and yeasts that cannot be excluded 
to be present. If the novel food or its source resembles a product mentioned in Regulation (EC) No 
2073/2005, it is advisable to include the micro-organisms mentioned in this regulation for this food 
product in the analysis. 
• Those contaminants introduced at primary production (like mycotoxins, pesticide residues), those 
formed during processing, transport, and storage, and those substances used in processing (like 
solvents) may have to be analysed. 
• Heavy metals (Cd, Pb, As, F, Hg, Ni), pesticide residues, mycotoxins, and other contaminants such 
as dioxins, dioxin-like PCBs, PCBs, PAHs, may have to be determined. 
• For protein products, analysis of the amino acid composition is advisable as this can be used to 
determine the nutritional value of the protein. The UK based ACNFP has provided guidelines11 for 
identifying and quantifying protein levels. Determination of a fatty acid profile for pure proteins is 
not required. However, for whole food products that contain fat, a fatty acid profile is helpful in the 
assessment of the nutritional value.  
• Parameters for isolated proteins may be: purity of the protein, solubility, pH 2% solution, amino acid 
composition, molecular mass, isoelectric point, absorption spectra, protease sensitivity, and heat 
stability. 
 
The measured levels of contaminants and residues should be compared to the legal limits for these 
compounds. EU and Dutch legislation on legal limits for contaminants and residues is listed in 
Table 3.3. 
 
Preferably, laboratory analyses for all compounds and organisms should be performed by accredited 
laboratories. Methods of analysis used should preferably be accredited and validated as far as 
possible, and, if possible, comply with EU rules on official methods of analysis and criteria for such 
methods. Accredited laboratories and methods in the Netherlands can be found at 
http://www.rva.nl/search/. EU legislation on official methods of analysis for contaminants and residues 
in food products is listed in Table 3.3. If available, samples to be analysed for contaminants and 
residues should preferably be taken using official methods mentioned in EU legislation (Table 3.3). 
Note that it is not always necessary to perform all analyses. The composition of the novel protein can 
be compared to compositions of similar proteins in published scientific observations. Like the levels of 
contaminants and residues, the levels of toxins and anti-nutrients in the novel protein can also be 
compared with those of substances in comparable common food sources which are already consumed 
in similar quantities, to show that the novel protein is safe. 
 
  
10 http://www.oecd.org/fr/env/ess/biotrack/consensusdocumentsfortheworkonharmonisationofregulatory 
oversightinbiotechnology.htm 
11 http://www.food.gov.uk/multimedia/pdfs/proteinsinnovelfoodsissuesforconsid.pdf 
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 Table 3.3 
Legal limits in food and official methods of analysis sampling. 
Contaminant(s)/residues Legal limits in food in EU and the 
Netherlandsa 
Official methods of analysis (and 
sampling) 
Dioxins, furans and dioxin-like PCBs, 
and non-dioxin-like PCBs in food 
Regulation (EC) No 1881/2006 Regulation (EU) No 252/2012 
Pd, Cd, Hg, inorganic tin, 3-MCPD, and 
PAHs in food 
Regulation (EC) No 1881/2006 Regulation (EC) No 333/2007 
Mycotoxins in food Regulation (EC) No 1881/2006 Regulation (EC) No 401/2006 
Nitrate in food Regulation (EC) No 1881/2006, 
Warenwetregeling verontreinigingen in 
levensmiddelen 
Regulation (EC) No 1882/2006 
Residues of plant protection products Regulation (EC) No 396/2005 Guideline SANCO/12495/2011, 
(Sampling: Directive 2002/63/EC) 
Residues of veterinary drugs Regulation (EU) No 37/2010 Decision 2002/657/EC, (Sampling: 
Decision 98/179/EC) 
(Residues of) extraction solvents Directive 2009/32/EC, 
Warenwetregeling extractiemiddelen 
 
Lysino-alanine Warenwetbesluit Eiwitproducten  
a The latest consolidated versions of EU legislation can be found at http://eur-lex.europa.eu/en/index.htm. Dutch legislation can be found at 
www.overheid.nl. Plant protection products’ MRLs can also be found in the Plant Pesticide Database 
http://ec.europa.eu/food/plant/pesticides/pesticides_database/index_en.htm 
 
 
The source of the novel protein has to be specified using scientific nomenclature and should include 
the Latin name. Taxonomic identity of the novel protein established should be according to referenced 
and internationally accepted principles, for example the International Code of Nomenclature for algae, 
fungi, and plants (ICN) and International Code of Zoological Nomenclature (ICZN). Any deviation from 
such principles should be explained. In general, providing the taxon to the level of species, 
subspecies, and variety is sufficient to uniquely identify the source of the novel protein. Possible 
databases for taxonomic identity are: 
• The 2010 EU Common Catalogue of Varieties of Agricultural Plant Species (http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2010:337A:0001:0660:EN:PDF). 
• http://www.eu-nomen.eu/portal/ 
• http://www.catalogueoflife.org/col/info/databases 
• http://www.ncbi.nlm.nih.gov/taxonomy 
• http://www.ipni.org/ipni/plantnamesearchpage.do 
 
Examples of the specification of the novel protein in application dossiers for authorisation  
Box 2 provides examples of how the specification of a novel protein can be described in an application 
dossier for authorisation. The application dossier of the Touchi extract of soybean provides an example 
about how to present information about the stability of the novel food during storage. 
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3.4.2 Effect of the production process applied to the novel protein 
Figure 3.2 (Scheme II of Recommendation 97/618/EC) refers to the effect of the production process 
applied to the novel protein. Table 3.4 provides the questions in scheme II, and information and 
suggestions to answer each question. 
 
 
  
Box 2: The specification of a novel food in the application dossiers for authorisation of 
Chia seeds and Touchi extract of soybean 
 
Chia seeds 
The specification is presented in chapter ‘I. Specification of the Novel Food’ of the application 
dossier (http://www.food.gov.uk/multimedia/pdfs/applicdosschiacompany.pdf) in the paragraphs: 
• Description: Latin name of Chia is Salvia hispanica L. belonging to the Labiatae family. 
• Composition of … 
• Potentially toxic inherent constituents, external contaminants and nutrients 
• Samples and specification representative of commercial scale and traceable 
 
 
Touchi extract of soybean 
The specification is presented in the chapter ‘I. Specification of the Novel Food’ of the application 
dossier (http://www.food.gov.uk/multimedia/pdfs/touchiapplication.pdf) in the paragraphs: 
I.A Identity: Latin name: ‘… small soybeans (Glycine max.) fermented with the fungus 
Aspergillus Oryzae’. 
I.A.1 Proposed Names  
I.A.2 Trade Names  
I.B Specification (table I.B-1)) 
I.C Analytical Information (presents batches used) 
I.C.1 Potentially Toxic Inherent Constituents and External Contaminants (Pesticides, heavy 
metals, dioxins and dioxin-like PCB’s, Polycyclic Aromatic Hydrocarbons (PAHs), 
mycotoxins, 3-Monochloropropane-1,2-diol (3-MCPD)) 
I.C.2 Nutrients (Nutrient profile, Isoflavone Aglycones Content, Enzyme Inhibitory Activity) 
I.D Representative Commercial Scale Batch Data  
I.E Formulation Data  
I.F Stability Data (in time, conditions) 
I.F.1 Stability of the Bulk Powder  
I.F.2 Stability Formulated Products 
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 Table 3.4 
Effect of the production process applied to the novel protein. 
Question from scheme II (Figure 3.2) Information and suggestions 
Does the novel food undergo a production process? 
 
Provide a detailed description of the production process, 
process conditions, and of intermediate products 
Describe the proposed methods to maintain effective control 
to comply with the specifications (Quality Management 
Systems such as HACCP, GMP, ISO, GlobalGAP). 
Add copies of certificates of these Quality Management 
Systems, if available. 
 
Is there a history of use of the production process for the 
food? 
 
Compare the process of the novel food with processes used 
for an existing food product. 
 
Does the process result in a significant change in the 
composition or structure of the novel food compared to its 
traditional counterpart? 
 
Compare the composition and/or structure of novel protein to 
the composition and/or structure of the protein in the source 
from which it was derived, or with comparable proteins in 
sources already consumed in the EU. 
 
Is information available to enable identification of the possible 
toxicological, nutritional and microbiological hazards arising 
from use of the process? 
 
See scheme I (figure 3.1), question 1. 
 
Are the means identified for controlling the process to ensure 
that the novel food complies with its specification? 
 
Describe agreed methods and specifications to maintain 
effective control thereby ensuring a high standard of food 
safety throughout the production process (QMS based on 
HACCP, traceability) 
Add copies of details and certificates HACCP etc. 
 
Has the process the potential to alter the levels in the novel 
food of substances with an adverse effect on public health? 
 
See question 4 
 
After processing is the novel food likely to contain 
microorganisms of adverse public health significance? 
 
See question 4 
 
After processing is the novel food likely to contain 
microorganisms of adverse public health significance? 
See question 4 
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Figure 3.2 Scheme II for the effect of the production process applied to a novel food (Source: 
Recommendation 97/618/EC). 
 
 
Details of information and suggestions about the questions in Scheme II for the effect of the 
production process applied to a novel protein 
A detailed description of the production processes and conditions used and of the intermediate 
products of the novel protein has to be provided. This includes possible transport and storage phases. 
The description in the application dossier should convince assessors that any residues or contaminants 
derived from apparatus and equipment and from chemical, physical or biological aids are controlled. 
The application dossier should describe how the product is monitored and how safety and quality are 
controlled during the production process including transport and storage based on a Quality 
Management System, e.g. HACCP, GMP, ISO, GLOBALGAP, to be put in place. The application dossier 
should provide evidence that the process would not result in an adverse impact on essential 
nutritional, toxicological and microbiological parameters of the novel protein. To do so, the processes 
of the novel protein could be compared to processes already used for existing food products to show 
that these do not result in food safety risk. 
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Examples of the effect of the production process applied to the novel food in application dossiers for 
authorisation 
Box 3 provides examples of how the effect of the production process applied to the novel food can be 
described in an authorisation dossier. 
 
 
 
3.4.3 History of the organism used as source of the novel protein 
Figure 3.3 (Scheme III of Recommendation 97/618/EC) refers to the history of the organism used as 
the source of the novel protein. Table 3.5 provides the questions in scheme III, and information and 
suggestions to answer each question. 
 
 
  
Box 3: The effect of the production process applied to a novel food in the application 
dossiers for authorisation of Chia seeds and Touchi extract of soybean 
 
Chia seeds 
The production process is presented in the chapter ‘II. Effects of the Production Process Applied to 
the Novel Food’ of the application dossier 
(http://www.food.gov.uk/multimedia/pdfs/applicdosschiacompany.pdf) in the paragraphs: 
• Growing of the crop 
• Harvest 
• Post-harvest 
• Storage 
• Transport 
 
Touchi extract of soybean 
The production process is presented in the chapter ‘II. EFFECT OF THE PRODUCTION PROCESS 
APPLIED TO THE NOVEL FOOD’ of the application dossier 
(http://www.food.gov.uk/multimedia/pdfs/touchiapplication.pdf) in the paragraphs: 
 
II.A Production Process 
II.A.1 Production of Fermented Black Beans 
II.A.2 Production of Touchi Extract 
II.B History of the Production Process 
II.C Identification of Potential Hazards 
II.C.1 Toxicological Hazards 
II.C.2 Nutritional Hazards 
II.C.3 Microbiological Hazards 
II.D Control of the Production Process 
II.E Potential for Adverse Effect on Public Health or Micro-organism Contamination 
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 Table 3.5 
Effect of the history of the organism used as the source of the novel protein. 
Question from scheme III (Figure 3.3) Information and suggestions 
Is the novel food obtained from a biological source, i.e. a 
plant, animal, or microorganism? 
 
Yes, proteins have a biological source. 
 
Is the source organism characterised? 
 
For a biological source such as a novel protein, this is the 
taxon from scheme I, question 3. 
 
Is there information to show that the source organism and/or 
foods obtained from it are not detrimental to human health? 
 
If available, provide evidence on human consumption of the 
source or existing products derived from this source in the 
EU and outside the EU. The more concrete and detailed 
information about sales and consumption is available, the 
better the evidence (see Table 2.1 for types of evidence). 
If available, provide evidence on the safe use of the source 
or existing products derived from this source in other 
applications, such as in personal care products, or safe 
human handling of the source (including skin contact), for 
example in a production process. 
If available, provide evidence on safe consumption by 
mammals or other animals of the source or existing products 
derived from the source. This evidence may be indicative for 
the novel protein not being detrimental to human health. 
If available, provide information on known food safety 
aspects of human consumption of the source or products 
derived from it. 
 
Is there information on the mean levels and ranges of the 
detrimental substances in the novel food derived from the 
organism? 
 
Provide the results of analysis for hazardous substances in 
the novel protein as asked in Scheme I, question 1. 
 
Does the information reflect extremes in production and 
processing conditions for the novel food? 
 
The composition of the novel protein as asked in scheme I, 
question 1 should be representative for the novel protein 
when produced for the commercial market and should reflect 
extremes in production and processing conditions. 
Provide description of quality control system to show how 
you deal with extremes in production and processing 
conditions. 
 
Is the information sufficient to assess potential consumer 
risk? 
If you can fill in scheme XI and XIII, this is yes. 
 
 
  
LEI 14-075 | 21 
  
Figure 3.3 Scheme III for history of the source organism of a novel food (Source: adapted version 
of the decision tree in Recommendation 97/618/EC. The questions about genetically modified 
organisms have been deleted, because these are no longer within the scope of the Regulation (EC) No 
258/97). 
 
 
Details of information and suggestions about the questions in Scheme III for the history of the source 
organism of a novel protein 
The source of the novel protein has to be identified in scientific nomenclature, which is also asked in 
scheme I, question 3. 
To show that the source of the novel protein is not detrimental to human health, evidence of human 
exposure to the source or existing derived products inside the EU or outside the EU can be used. An 
important part of human exposure is consumption. The types of evidence of a history of human 
consumption to establish substantial equivalence (see Table 2.1) can also be used to show human 
consumption of the source or derived products. The more concrete and detailed information about 
consumption and sales is available, the better the evidence. Next to the historical use of the source or 
existing derived products in human consumption, the historical use in animal nutrition and in other 
applications, such as in personal care products, can be part of the evidence that the novel protein is 
safe. 
 
Examples of the effect of history of the source organism of the novel protein in application dossiers for 
authorisation 
Box 4 provides examples of how the effect of the history of the source organism of the novel protein 
can be described in an application dossier for authorisation. 
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3.4.4 Anticipated intake/extent of use of the novel protein 
Figure 3.4 (Scheme IX of Recommendation 97/618/EC) refers to the anticipated extent of use and 
intake of the novel protein. Table 3.6 provides the questions in scheme IX, and information and 
suggestions to answer each question. 
 
  
Box 4: The history of the source organism of a novel food in the application dossiers for 
authorisation of Chia seeds and Touchi extract of soybean 
 
Chia seeds 
The history of the organism used as source is presented in the chapter ‘III. History of the Source 
Organism’ of the application dossier 
(http://www.food.gov.uk/multimedia/pdfs/applicdosschiacompany.pdf) in the paragraphs: 
• Chia seed Source, GM Status, and Taxonomy 
• Information on Detrimental Health Effects 
 
Touchi extract of soybean 
The history of the organism used as source is presented in the chapter ‘III. HISTORY OF THE 
ORGANISM USED AS THE SOURCE OF THE NOVEL FOOD ’ of the application dossier 
(http://www.food.gov.uk/multimedia/pdfs/touchiapplication.pdf) in the paragraphs: 
III.A. Source of Touchi Extract 
III.A.1 Identity of the Soybean 
III.A.2 Cultivation of the Soybean 
III.A.3 Fermentation of the Soybean 
III.B GM Status of Touchi Extract 
III.C Characterisation of the Small Soybean 
III.D Characterisation of Aspergillus Oryzae 
III.E Potential for Detrimental Effects on Human Health 
III.E.1 Source Soybeans 
III.E.2 Aspergillus Oryzae 
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 Table 3.6 
Effect of the anticipated extent of use and intake of the novel protein. 
Question from scheme IX (Figure 3.4) Information and suggestions 
Is there information on the anticipated uses of the novel food 
based on its properties? 
 
Describe the intended use and purpose of the novel protein. 
The intended use can for example be use as food as such 
(like an apple), use as a food ingredient or use as an 
ingredient of a food supplement. The intended purpose can 
be nutritional (e.g. use as a source of protein), functional, or 
for beneficial effects. 
 
Is there information to show anticipated intakes for groups 
predicted to be at risk? 
 
Describe the intended quantity of inclusion in food products, 
diets or food supplements. 
Estimate levels of intake of the novel protein based on the 
intended quantity of inclusion in the human diet. Distinguish 
in intake of different population groups (like male, female, 
young, old), and include groups whose intake might be 
different from general population groups due to deviating 
consumption habits (e.g. vegetarian, vegan, halal, etc.). If 
necessary also take into account more vulnerable 
subpopulations (e.g. with deviating functioning of the 
immune system, genetically challenged, etc). 
If available, use data from food consumption surveys to 
estimate the potential intakes of your novel protein.  
If available, use consumption data from multiple member 
states to assure coverage of differences in intake levels due 
to differences in diets between member states. 
If possible, assess mean and 90th, 95th, and 97.5th percentile 
levels of intake. 
Include worst-case scenarios of consumers with the highest 
intakes in EU. 
Preferably, use the most recent consumption survey data. 
If you did identify special consumer groups (like vegan, 
vegetarian, etc), consumption data for these groups might 
be lacking. If this is the case, use literature or expert 
information to estimate intake levels. 
 
Will introduction of the novel food be restricted 
geographically? 
 
Describe region of market introduction in the EU. In most 
cases this will be the EU. 
 
Do intake figures reflect this limited distribution of the NF? 
 
Are figures from question 2 representative for region of 
question 3? In most cases no limited distribution is intended 
and this question is thus not applicable. 
 
Will the novel food replace other foods in the diet? 
 
Describe which foods or food ingredients the novel protein 
will replace and in what percentages or amount the novel 
protein will replace an existing protein/product. 
Note that this information should be used in the intake 
assessment of the novel protein. 
 
Are any of the replaced foods significant nutritional 
resources? 
 
If you answer question 4 in Scheme XI, you have answered 
this question as well. 
 
Does the probable level of substitution have a nutritional 
significance for any population groups? 
If you answer question 4 in Scheme XI, you have answered 
this question as well. 
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Figure 3.4 Scheme IX for anticipated extent of use and intake of the novel protein (Source: 
Recommendation 97/618/EC). 
 
Details of information and suggestions about the questions in Scheme IX about the anticipated extent 
of use and intake of the novel protein 
Indicate the intended use, purpose and quantity of consumption of the novel protein. The intended 
uses can for example be: use as a food product, use as a food ingredient or use as or in a food 
supplement. The purpose can be nutritional (source of protein), functional, or beneficial effects. The 
quantity indicates the maximum amount (in grams) of the novel protein a person will ingest (e.g. per 
day). Table 3.7 provides an example of how to present intended use categories and the maximum 
intended usage levels per category. 
 
 
Table 3.7:  
Example of intended use and purpose and the maximum intended usage levels per category. 
Food category Proposed food use Maximum use-level 
(mg/serving) 
Serving size (g) Maximum use-level 
(mg/100g) 
Milk and milk 
products 
Ice cream    
 Milk beverages    
 Yoghurts    
 
LEI 14-075 | 25 
 
The intended use levels for all products in which the novel protein is proposed to be used should be 
taken as a starting point of the intake assessment. This assessment should be based on food 
consumption data of consumers from multiple EU member states, since diets differ between the 
member states. Using data from recent food consumption surveys is advisable. Food consumption 
data for different EU member states can be found in the EFSA Comprehensive European Food 
Consumption Database available at the EFSA website12. These food consumption survey data can be 
used to assess mean and higher percentile levels (90th, 95th, 97.5th) of intake. If specific consumer 
groups might have a higher risk, e.g. due to age or gender, the intake of these specific consumer 
groups should also be estimated. For special consumer groups and groups with high intakes, intake 
estimates could also be derived from literature or based on expert judgement (if no other sources are 
available). For ‘worst-case’ high estimates, intake estimates should be on the ‘safe’ side. A worst-case 
scenario for the highest intake in the EU is advisable, especially if in this scenario the intake is far 
below the intake where adverse effects might be noted. Table 3.8 provides an example of estimated 
daily intake in different population groups in (m)g per person per day and in (m)g per kg body weight 
per day. Another model for estimating daily intakes is the model13 DEEM-FCID of the Environmental 
Protection Agency in the USA (DEEM-FCID: Dietary Exposure Evaluation Model-Food Commodity 
Intake Database). Although developed to estimate the dietary exposure to pesticides residues, this 
model could also be used as an example of an estimation of the intake. 
When a novel protein is to be used as a novel source of protein in the diet, a crude estimate of the 
intake may suffice. In this case, the novel protein should be assumed to replace a common other 
protein in all products in which this common protein is present. 
For food supplements, the recommended intake of the supplement determines the maximum intake. It 
is recommended to define different dose levels for different age groups or genders. 
 
 
Table 3.8 
Example of estimated daily intake in population groups (UK population groups based on the NDNS 
consumption data). 
Population group Age group 
(years) 
% user Actual # 
of total 
users 
All person consumption All users consumption 
Mean 
(mg) 
Percentile (mg) Mean 
(mg) 
Percentile (mg) 
90th 95th 97.5th 90th 95th 97.5th 
Children 1.5-4.5           
Young people 4-10           
Female teenagers 11-18           
Male teenagers 11-18           
Female adults 16-64           
Male adults 16-64           
 
Examples of anticipated extent of use and intake of the novel protein in application dossiers for 
authorisation 
 
Box 5 provides examples of the description of anticipated extent of use and intake of the novel protein 
in an application dossier for authorisation. 
 
12 http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb.htm 
13 http://www.epa.gov/oppfead1/cb/csb_page/updates/2013/deem.html 
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3.4.5 3.4.5. Information from previous human exposure to the novel protein or 
its source 
Figure 3.5 (Scheme X of Recommendation 97/618/EC) refers to the information of previous human 
exposure of the novel protein or its source. Table 3.9 provides the questions in scheme X, and 
information and suggestions to answer each question. 
 
 
Table 3.9  
Information of previous human exposure to the novel protein or its source. 
Question from scheme X (Figure 3.5) Information and suggestions 
Is there information from previous direct, indirect, intended, 
or unintended human exposure to the novel food or its 
source which is relevant to the Community situation with 
respect to production, preparation, population, lifestyles and 
intakes? 
 
Provide detailed information on previous human exposure to 
source of the novel protein inside the EU and outside the EU, 
if available. This is the same information as asked in Scheme 
III, question 3. 
Provide detailed information on previous human exposure to 
the novel protein outside EU, if available. 
Exposure can be oral, but also dermal like via skin contact 
during handling or use in other applications such as personal 
care products, or via inhalation. 
If available, provide evidence on safe consumption by 
mammals or other animals of the source or existing products 
derived from the source. This evidence may be indicative for 
the novel protein not being detrimental to human health. 
Provide evidence of human exposure across the world, if 
available.  
Is there information to demonstrate that exposure to the 
novel food is unlikely to give rise to nutritional, 
microbiological, toxicological and/or allergenicity problems? 
Provide information about nutritional, microbiological, 
toxicological and/or allergenicity problems that have 
occurred due to exposure (oral, dermal, via inhalation) to the 
source of novel protein, to existing products derived from the 
source of the novel protein, and to the novel protein. 
 
 
  
Box 5: The anticipated extent of use and intake of a novel food in the application 
dossiers for authorisation of Chia seeds and Touchi extract of soybean 
 
Chia seeds 
Anticipated extent of use and intake is presented in the chapter ‘IX Anticipated Intake/Extent of 
Use’ of the application dossier 
(http://www.food.gov.uk/multimedia/pdfs/applicdosschiacompany.pdf) in the paragraphs: 
• Intended Uses 
• Current Position 
o Anticipated Intake 
• 100% Chia seed as a Consumer Product 
• Intake for Groups Predicted to be at Risk 
• Geographic restriction of Chia seed Release 
• Will Chia seed replace other foods in the diet? 
• Labelling 
 
Touchi extract of soybean 
Anticipated extent of use and intake is presented in the chapter ‘IX ANTICIPATED INTAKE/EXTENT 
OF USE OF THE NOVEL FOOD’ of the application dossier 
(http://www.food.gov.uk/multimedia/pdfs/touchiapplication.pdf) in the paragraphs: 
IX.A Anticipated Food Uses and Maximum Use Level 
IX.A.1 Intended Use and Use-Levels 
IX.A.2 Consumer Awareness 
IX.A.3 Exposure Estimates 
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Figure 3.5 Scheme X for information of previous human exposure to a novel food or its source 
(Source: Recommendation 97/618/EC). 
 
 
Details of information and suggestions about the questions in Scheme X about the information of 
previous human exposure to a novel protein or its source 
In this chapter, the results of a thorough search of documented use of the NF by humans in third 
countries or the documented use of the source organism by humans in the EU and in third countries 
have to be provided. This has overlap with Scheme III, question 3 about the history of the source 
organism of the novel protein, in which information must be provided on human exposure to the 
source of the novel protein. In this chapter, the information provided in Scheme III, question 3 can be 
referred to, and information about human exposure to the novel protein itself outside the EU can be 
added. The types of evidence of a history of human consumption to establish substantial equivalence 
(see Table 2.1) can also be used to show human consumption of the source or derived products. The 
more concrete and detailed information about sales and consumption is available, the better the 
evidence. In addition to the historical use of the source or existing derived products in human 
consumption, the historical use in other applications, such as in personal care products, can be part of 
the evidence that the novel protein is safe. 
 
Examples of information of previous human exposure to a novel food or its source in application 
dossiers for authorisation 
 
Box 6 provides examples of the information on previous human exposure to a novel food or its source 
for an application dossier for authorisation. 
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3.4.6 Nutritional information on the novel protein 
Figure 3.6 (Scheme XI of Recommendation 97/618/EC) refers to the nutritional information on the 
novel protein. Table 3.10 provides the questions in scheme XI, and information and suggestions to 
answer each question. 
 
 
Table 3.10 
Nutritional information on the novel protein. 
Question from scheme XI (Figure 3.6) Information and suggestions 
Is there information to show that the novel food is 
nutritionally equivalent to existing foods that it might replace 
in the diet? 
 
Provide the nutritional information of the novel protein as 
presented in Scheme I question 1, and compare this with the 
composition of the existing protein you aim to replace in the 
diet. 
In case of (very) low intake levels compared to total dietary 
protein intake it might be possible to draw the conclusion 
that intake would not be nutritiously disadvantageous 
without taking into consideration parameters like amino acid 
composition or digestibility of the protein.  
 
Is there information to show that the novel food does not 
affect the bioavailability of nutrients from the diet or have 
any adverse physiological effects? 
 
Nutritional consequences should be established at normal 
and maximum levels of consumption, comparable to scheme 
IX, question 2. 
Is information available to allow a balance to be made 
between risks and benefits? 
 
Most of the times no specific information will be available. 
You can make some general remarks on the increased 
sustainability of the source of your novel protein or other 
beneficial aspects of the novel protein. 
 
Is there information to allow an assessment to be made of 
the nutritional impact of the introduction of the novel food? 
Provide information on potential shifts in intake in 
(micro)nutrients in (sub)populations due to introduction of 
your novel protein in the diet based on intake levels of the 
novel protein (Scheme IX, question 2) and nutrient levels in 
the novel protein (Scheme XI, question 1). 
 
 
 
 
Box 6: The information on previous human exposure to a novel food or its source in the 
application dossiers for authorisation of Chia seeds and Touchi extract of soybean 
 
Chia seeds 
Information about previous human exposure is presented in the chapter ‘X. Information on 
Previous Human Exposure’ of the application dossier 
(http://www.food.gov.uk/multimedia/pdfs/applicdosschiacompany.pdf) in the paragraphs: 
• Recent Human Exposure to Chia seed 
• Consumption Recent History 
• Global Regulatory Approvals for Chia Seed 
• Investigation into Allergic Reactions to Chia 
• Conclusion on Previous Human Exposure 
• Nutritional, Microbiological, and Toxicological Information related to Chia seed Exposure 
 
Touchi extract of soybean 
Information about previous human exposure is presented in the chapter ‘X. Specification of the 
Novel Food’ of the application dossier 
(http://www.food.gov.uk/multimedia/pdfs/touchiapplication.pdf) in the paragraphs: 
X. INFORMATION FROM PREVIOUS HUMAN EXPOSURE TO THE NOVEL FOOD OR ITS SOURCE 
X.A Previous Human Exposure 
X.B Allergenicity of Touchi Extract 
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Figure 3.6 Scheme XI for the nutritional information on a novel food (Source: Recommendation 
97/618/EC). 
 
 
Details of information and suggestions about the questions in Scheme XI about the nutritional 
information on a novel protein 
Nutritional effects are not to be expected if novel protein intake levels are estimated to be low and the 
change in human diet is minimal. Thus, in case of (very) low estimated intakes, this reasoning will be 
sufficient to conclude that there will be no nutritional impact. If the novel protein is meant to replace 
an existing protein in the diet, estimates of intakes will be higher. In this case, the analytical data on 
the composition (see Scheme I) and estimated intake (see Scheme IX) can be used to compare intake 
of proteins, amino acids, and other (macro and micro) nutrients in diets containing the novel protein 
to intake of nutrients from the ‘old’ diet to assess the nutritional impact. Recommended daily 
intake/amounts or reference values for nutrient intake could also be used to evaluate the nutritional 
impact.  
Nutritional studies in animals are hardly ever considered to be necessary by CAs of EU member states. 
However, if you want to test your novel protein in nutritional studies in experimental or farm animals, 
the novel protein should be compared to a similar protein that is commonly used in animal diets. The 
only difference between the novel and common diets should be the protein used (thus protein content 
and also amino acid composition of the diets with the novel protein and the similar protein should be 
the same). Furthermore, diets should be used that are not nutritiously disadvantageous for animals. 
 
Examples of the nutritional information on a novel food in application dossiers for authorisation 
 
Box 7 provides examples of the nutritional information in an application dossier for authorisation. 
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3.4.7 Microbiological information on the novel protein 
Figure 3.7 (Scheme XII of Recommendation 97/618/EC) refers to the microbiological information on 
the novel protein. Table 3.11 provides the questions in scheme XII, and information and suggestions 
to answer each question. 
 
 
Table 3.11 
Microbiological information on the novel protein. 
Question from scheme XII (Figure 3.7) Information and suggestions 
Is the presence of any microorganisms or their metabolites 
due to the novelty of the product/process? 
 
The source of your novel protein or the way of processing 
might be indicative of the presence or introduction of certain 
micro-organisms. Refer to scheme I specifications of your 
product (microbiological part). 
 
Is there information to show that the NF is unlikely to 
contain microorganisms and/or their metabolites of adverse 
public health significance? 
 
Mention if sterilisation or sufficiently high temperatures are 
used in the process because then it is unlikely that the 
product will contain micro-organisms. Add the information 
about microbiological content measured in Scheme I, 
question 1. 
 
Is the NF likely to be confused with existing foods? 
 
Refer to scheme I, question 1 and use the appearance in 
your specification (method visual). 
Is information available to allow the development of 
procedures to ensure that the NF is appropriately handled, 
cooked or processed before consumption? 
 
Provide the information you aim to provide to buyers of the 
novel protein on how to handle and use the novel protein. 
Describe how you provide the information mentioned in the 
first bullet to your buyers. 
 
Are the procedures for handling, cooking or processing the 
existing food adequate to ensure safety if applied to the NF? 
If the novel protein is similar to an existing protein, you can 
also mention that the safety procedures for the existing 
protein will also work for the novel protein. 
Describe how you provide the information mentioned in the 
first bullet to your buyers. 
 
Box 7: The nutritional information in the application dossiers for authorisation of Chia 
seeds and Touchi extract of soybean 
 
Chia seeds 
Nutritional information is presented in the chapter ‘XI. Chia Nutritional Profile’ of the application 
dossier (http://www.food.gov.uk/multimedia/pdfs/applicdosschiacompany.pdf) in the sub-chapters: 
• Statement of Nutritional Profile 
• Chia seed Nutritional Equivalence to Food it Might Replace 
• Bioavailability of Nutrients and Nutritional Impact of Chia seed 
• Heavy Metals and Chemical Contaminants 
 
Touchi extract of soybean 
Nutritional information is presented in the chapter ‘XI. NUTRITIONAL INFORMATION ON THE NOVEL 
FOOD’ of the application dossier (http://www.food.gov.uk/multimedia/pdfs/touchiapplication.pdf) in 
the sub-chapters: 
XI.A Comparison of Touchi Extract to Traditional Counterparts 
XI.A.1 Soy Proteins 
XI.A.2 Soy Isoflavones 
XI.A.3 Alpha-glucosidase Inhibitory Action 
XI.B Labelling of Touchi Extract 
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Figure 3.7 Scheme XII for the microbiological information on a novel food (Source: 
Recommendation 97/618/EC). 
 
 
Details of information and suggestions about the questions in Scheme XII about the microbiological 
information on a novel protein 
Applicants should provide data on microbiological tests performed on at least four batches of the novel 
protein taking into account, if appropriate, at least the micro-organisms and methods listed in 
Regulation (EC) No 2073/2005.  
If the analysis in Scheme IX, question 2 included micro-organisms, referring to the results of Scheme 
IX, question 2 is sufficient here. It is also possible to describe the hazard analysis used to identify 
microbiological hazards, and the way these hazards are controlled in your HACCP system. This 
description should also include the stages of storage and transport. 
 
The storage, handling, and processing of the novel protein should be specified to ultimately ensure the 
microbiological safety of the consumer products that contain the novel protein. 
 
Examples of the microbiological information on a novel food in application dossiers for authorisation 
Box 8 provides examples of microbiological information in an application dossier for authorisation. 
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3.4.8 Toxicological information on the novel protein 
Figure 3.8 (Scheme XIII of Recommendation 97/618/EC) refers to the toxicological information of the 
novel protein. Table 3.12 provides the questions in scheme XIII, and information and suggestions to 
answer each question. 
 
 
  
Box 8: The microbiological information in the application dossiers for authorisation of 
Chia seeds and Touchi extract of soybean 
 
Chia seeds 
Microbiological Information of the Chia Seed is presented in the chapter ‘XII. Microbiological 
Information of the Chia Seed’ of the application dossier 
(http://www.food.gov.uk/multimedia/pdfs/applicdosschiacompany.pdf). 
 
Touchi extract of soybean 
Microbiological information is presented in the chapter ‘XII. MICROBIOLOGICAL INFORMATION ON 
THE NOVEL FOOD’ in sub-chapter ‘XII.A Information on Microorganisms and their Metabolites’ of 
the application dossier (http://www.food.gov.uk/multimedia/pdfs/touchiapplication.pdf). 
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 Table 3.12 
Toxicological information of the novel protein. 
Question from scheme XIII (Figure 3.8) Information and suggestions 
Is there a traditional counterpart to the NF that can be used 
as a baseline to facilitate the toxicological assessment? 
 
If possible, use the existing protein that you aim to replace 
as traditional counterpart. 
Alternatively, you can use a product from a taxonomically 
related food source. 
 
Is there information from a range of toxicological studies 
appropriate to the NF to show that the NF is safe under 
anticipated conditions of preparation and use? 
 
Include here all data you can find on the history of the safety 
of the source, on the composition / specifications of your 
novel protein, and on the use in food or feed, demonstrating 
no adverse effects on human or mammal health when 
consumed in a comparable way, supported by any existing 
toxicological studies. The specifications of your product 
(Scheme I) might waiver the supply of toxicological studies. 
 
Compared to the traditional counterpart, does the NF contain 
new toxicants or changed levels of existing toxicants? 
 
Provide the information of the novel protein as presented in 
Scheme I question 1, and compare this with the composition 
of the existing protein you aim to replace in the diet. 
If applicable compare levels of toxicants (contaminants, 
residues, anti nutritional substances,, toxins, etc) with legal 
limits. 
 
Is there information which suggests that the NF might pose 
an allergenic risk to humans? 
 
At present, validated testing methods to predict the 
allergenicity of a novel protein are not available. Some 
information on the potential allergenicity can be derived 
from: 
Literature data on the allergenicity of the source of the novel 
protein due to consumption, skin contact, or inhalation. 
Literature data on the allergenicity of species related to the 
source of the novel protein. 
A search for amino acid sequence and/or structural 
similarities between the novel proteins(s) and known 
allergens in in international databases. 
 
Is there sufficient information to allow the potential 
allergenicity of the NF to be monitored? 
 
In case the novel protein is related to existing proteins with a 
known allergenic risk, propose labelling of products 
containing your novel protein. 
 
Has the level of allergenicity been determined in controlled 
trials? 
 
Most likely there are no controlled trials but if trials have 
been performed, describe them. 
Are the levels in the NF of these new toxicants or existing 
toxicants no higher than those found in other foods with a 
history of food use in the Community? 
 
Compare levels of antinutritional constituents and 
contaminants (as in Scheme 1) to legal limits or levels of 
these substances in other foods that are already on the 
market. 
Refer to the information provided in question 3 of this 
Scheme. 
 
Is there information to show that the consumption of the NF 
will not raise intakes of the toxicants to unacceptable levels? 
 
Intake levels of toxic substances should be established at 
normal and maximum consumption levels, comparable to 
scheme IX, question 2. 
Compare the results on intake of the first bullet with 
Acceptable Daily Intake (ADI), Tolerable Daily Intakes (TDI), 
Acute Reference Dose (ARfD) or other human health limits 
established for the specific toxic substances. 
 
Is there information to show that the presence of these 
toxicants in the NF will not be a cause for concern? 
 
See question 8 of this Scheme. 
 
Is there information which suggests that the NF might pose 
an allergenic risk to humans? 
See question 4 of this Scheme. 
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Figure 3.8 Scheme XIII for the toxicological information on a novel food (Source: Recommendation 
97/618/EC). 
 
 
Details of information and suggestions about the questions in Scheme XIII about the toxicological 
information on a novel protein 
For novel proteins to be used as a source of protein, toxicity studies in experimental animals are 
hardly required by CAs of member states. A detailed and adequate analysis of the composition 
(including naturally occurring substances, contaminants formed during processing, and other 
substances known to be toxic) and an adequate description of the source of the protein, will usually be 
sufficient.  
 
Some applicants may wish to place novel proteins on the market bearing claims of beneficial effects. 
This guideline does not describe the substantiation of claims. However, if efficacy studies in humans 
are performed, parameters addressing potential adverse effects could be included making these 
studies more valuable for the safety assessment. 
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If studies in experimental animals are performed, the applicant should make sure that OECD 
(http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-testing-of-chemicals-section-4-
health-effects_20745788) or other international guidelines for these studies are taken into account, 
that studies are performed under Good Laboratory Practices conditions, and that the material tested is 
described properly (and is identical or highly equivalent to the novel food product). An applicant 
should provide complete copies of the study reports (including individual animal data). 
 
A thorough and adequate search of scientific literature on reported (adverse) effects of the source of 
the novel protein in humans and animals, (levels of) contaminants, toxins, anti-nutritional substances 
etc. should be included to substantiate safety of the novel protein. Complete copies of all relevant 
literature should be included in your application dossier. Estimated intakes of those hazardous 
substances in the novel protein can be compared to human health limits (like Acceptable Daily Intakes 
(ADI), Tolerable Daily Intakes (TDI), and Acute Reference Dose (ARfD)) established by EFSA, or other 
risk assessment bodies such as Joint FAO/WHO Expert Committee on Food Additives (JECFA), Joint 
FAO/WHO Meeting on Pesticide Residues (JMPR), Environmental Protection Agency (EPA) in the USA, 
and Food and Drug Administration in the USA (FDA). Lower estimated intakes than established health 
limits can be evidence of safety of the novel protein. 
 
Allergenic potential of proteins 
For assessing the allergenic potential of proteins, ACNFP (2011)14 advices to use the EFSA guide 
‘Scientific Opinion on the assessment of allergenicity of GM plants and microorganisms and derived 
food and feed’ (EFSA, 2010)15. 
Allergic reactions can be expected when the novel protein or the source of the novel protein is similar 
to food products that already need to be labelled due to their allergenicity (as listed in Annex IIIa of 
Directive 2000/13/EC). When an allergic reaction is expected, the applicant should include a labelling 
proposition in the novel food dossiers.  
For those novel proteins that are supposed to be used in a hydrolysed form, peptide lengths in the 
hydrolysed product should be determined with adequate analysis methods. Only if the size of the 
peptides makes it very unlikely that a sensitised person will react to the product, labelling can be 
wavered. 
If an appropriate literature search does not reveal any indications of allergic reactions to the source of 
the product (including search for contact dermatitis in those handling the product), and other products 
from related source families, then this will suffice to conclude the novel protein is not allergenic. 
However, very often, the source will be related to other sources known to induce allergies. In this 
case, it may be necessary to perform a homology search for all proteins in the products with known 
allergens in international databases, such as the allergen online database16. A possibility is to derive 
amino acid sequences from the DNA sequence of the source organism and to compare these with a 
databank of known allergens. 
 
Examples of the toxicological information on a novel food in application dossiers for authorisation 
Box 9 provides examples of toxicological information on a novel food in an application dossier for 
authorisation. 
 
14 http://www.food.gov.uk/multimedia/pdfs/proteinsinnovelfoodsissuesforconsid.pdf. 
15 http://www.efsa.europa.eu/en/efsajournal/doc/1700.pdf. 
16 Allergen online database available at http://www.allergenonline.org/. 
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3.5 Evaluation and conclusion by the applicant 
The applicant has to evaluate all the information provided in the former chapters and conclude on the 
safety for human consumption of the novel protein. The evaluation and the conclusion you draw can 
only be based on information presented in the application dossier. Box 10 provides examples of the 
conclusion in an application dossier for authorisation. 
 
 
 
3.6 Summary by the applicant 
The applicant has to summarise all the information provided in the former chapters and draw 
conclusions on the safety for human consumption of the novel protein. Box 11 provides examples of 
the summary in an application dossier for authorisation. 
 
 
 
  
Box 9: The toxicological information in the application dossiers for authorisation of Chia 
seeds and Touchi extract of soybean 
 
Chia seeds 
Toxicological information is presented in the chapter ‘XIII. Toxicological Information of the Chia Seed’ 
of the application dossier (http://www.food.gov.uk/multimedia/pdfs/applicdosschiacompany.pdf) in 
sub-chapter ‘Allergy’. 
 
Touchi extract of soybean 
Toxicological information is presented in the chapter ‘XIII. TOXICOLOGICAL INFORMATION ON THE 
NOVEL FOOD’ of the application dossier 
(http://www.food.gov.uk/multimedia/pdfs/touchiapplication.pdf) in the sub-chapters: 
XIII.A Experimental Animal Data 
XIII.A.1 Acute Toxicity 
XIII.A.2 Subacute / Subchronic Toxicity 
XIII.A.3 Reproductive/Developmental Toxicity 
XIII.A.4 Mutagenicity/Genotoxicity  
XIII.A.5 Chronic Toxicity 
XIII.A.6 Other Preclinical Studies 
XIII.B Human Data 
Box 10: The conclusion in the application dossiers for authorisation of Chia seeds and 
Touchi extract of soybean 
 
Chia seeds 
The conclusion is presented in the chapter ‘Conclusions’ of the application dossier 
(http://www.food.gov.uk/multimedia/pdfs/applicdosschiacompany.pdf). 
 
Touchi extract of soybean 
The conclusion is presented in the chapter ‘OVERALL CONCLUSIONS’ of the application dossier 
(http://www.food.gov.uk/multimedia/pdfs/touchiapplication.pdf). 
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Box 11: The summary in the application dossiers for authorisation of Chia seeds and Touchi 
extract of soybean 
 
Chia seeds 
The summary is presented in the chapter ‘Executive summary’ of the application dossier 
(http://www.food.gov.uk/multimedia/pdfs/applicdosschiacompany.pdf). 
 
Touchi extract of soybean 
The summary is presented in the chapter ‘EXECUTIVE SUMMARY’ of the application dossier 
(http://www.food.gov.uk/multimedia/pdfs/touchiapplication.pdf). 
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 4 Application dossier for notification 
(substantial equivalence) 
Article 5 of Regulation (EC) No 258/97 on novel foods and novel food ingredients provides a simplified 
procedure for a person, producer, or importer to bring a novel protein to the market that is 
‘substantially equivalent’ to an existing counterpart (product) already allowed on the EU market. 
Substantial equivalence has to be demonstrated in an application dossier for notification. This dossier 
has to be submitted to a local CA for novel foods in an EU member state. This chapter handles 
instructions, practical tips, and examples for application of dossiers for notification. 
 
Applicants of an application dossier for notification could use the guidelines from the UK’s ACNFP17 and 
the Dutch Gezondheidsraad18 (in Dutch), which provide information to prove the substantial 
equivalence of a novel food to an existing counterpart. The main structure of the chapters of an 
application dossier for notification of a novel protein is: 1. basic administrative information; 2. general 
description and composition; 3. nutritional value; 4. metabolism; 5. intended use; 6. level of 
undesirable substances, and 7. any other relevant information on the novel protein. 
 
Previously approved applications dossiers for notification can aid in making an application dossier for a 
novel protein. Box 12 provides examples of application dossiers for notification of refined Buglossoides 
oil, Chia seeds and DHA-rich algal oil from Schizochitrium Sp.ONC-T18 assessed by the UK’s ACNFP. 
The examples show the public parts of the application dossiers. More application dossiers for 
notification of novel foods assessed by the ACNFP can be found on their website19 under ‘Simplified 
procedure’. 
 
 
 
  
17 http://www.food.gov.uk/multimedia/pdfs/seguidelines.pdf 
18 Instructions on page 31 of ‘Veiligheidsbeoordeling van nieuwe voedingsmiddelen (2)’ available at http://www.cbg-
meb.nl/NR/rdonlyres/4B55FA07-6E31-4037-A0D4-F62ABE0FC237/0/200723.pdf 
19 http://acnfp.food.gov.uk/assess/. 
Box 12: The public part of application dossiers for notification of Refined Buglossoides oil, 
Chia seeds and DHA-rich algal oil from Schizochitrium Sp.ONC-T18 
 
Refined Buglossoides oil 
The application dossier for notification is available at 
http://www.food.gov.uk/multimedia/pdfs/buglossoides-arvensis-application.pdf. 
 
Chia seeds 
Two application dossiers for notification are available at 
http://www.food.gov.uk/multimedia/pdfs/chiaappinvagrop.pdf and 
http://www.food.gov.uk/multimedia/pdfs/chiaappinfood.pdf. 
 
DHA-rich algal oil from Schizochitrium Sp.ONC-T18 
The application dossier for notification is available at 
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 4.1 Administrative data 
The following administrative data are needed: 
• Name, postal and email address, telephone and fax of the applicant of the application dossier. 
• Name, postal and email address, telephone and fax of the producer of the novel protein. 
• Name, postal and email address, telephone and fax of the person responsible for the application 
dossier. 
• Date of the application. 
• Name of the novel protein. 
4.2 General description and composition 
The application dossier for notification should contain a specification of the novel protein, including 
information on the source organism, methods used for preparation, the composition of the final 
product and specification (minimum, maximum, average) of levels of contaminants, residues, and, if 
applicable, endogenous toxins. The composition of the novel equivalent product should be compared 
to the composition of one existing counterpart. This counterpart should be described in the same level 
of detail. The novel protein and the existing counterpart should be derived from the same or very 
similar species, and if applicable, grown and harvested under similar conditions. This requirement may 
be less strictly, if the products are refined extracts that contain only a limited number of defined 
chemical components. 
4.2.1 Information on source organism 
Taxonomic identity of the source of the novel protein has to be specified in scientific nomenclature 
using the Latin name. This should be established according to referenced and internationally accepted 
principles (for example the International Code of Nomenclature for algae, fungi, and plants (ICN) and 
International Code of Zoological Nomenclature (ICZN)). Any deviation from such principles should be 
explained. In general providing the taxon to the level of species, subspecies, and variety is sufficient 
to uniquely identify the source of the novel protein. Possible databases for taxonomic identity are: 
• The 2010 EU Common Catalogue of Varieties of Agricultural Plant Species (http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2010:337A:0001:0660:EN:PDF). 
• http://www.eu-nomen.eu/portal/ 
• http://www.catalogueoflife.org/col/info/databases 
• http://www.ncbi.nlm.nih.gov/taxonomy 
• http://www.ipni.org/ipni/plantnamesearchpage.do 
 
Box 13 provides four examples of Chia seeds, DHA-rich algal oil from Schizochitrium Sp.ONC-T18, 
Refined Buglossoides oil and Saskatoon berry to present taxonomic information in an application 
dossier for notification. 
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4.2.2 History of use 
Evidence of human exposure to the source or existing derived products can be used to show that the 
source of the novel protein is not detrimental to human health. This concerns human exposure inside 
and outside the EU. The exposure to humans will be dosed via oral consumption. Table 2.1 provides 
types of evidence of a history of human consumption. The more concrete and detailed information on 
sales and consumption is available, the better the evidence. Exposure via skin contact or use in other 
applications, such as personal care products, can also be part of the evidence that the novel protein is 
safe. If available, detailed information on use of the source of the novel protein or existing derived 
products in animal feed for mammals or other animals should be provided. This could give indications 
for the novel protein being not detrimental to human health. Box 14 provides an example of history of 
use of Chia seeds in the application dossier for notification. 
 
 
 
4.2.3 Product specification 
The proposed product specification should be compared to the product specification of the existing 
counterpart. Box 15 provides an example of the product specification of refined Buglossoides oil 
compared to that of Echium Oil in the application dossier for notification. 
 
 
 
Box 13: Taxonomic information in the application dossiers for notification of Chia seeds, 
DHA-rich algal oil from Schizochitrium Sp.ONC-T18, refined Buglossoides oil and Saskatoon 
berry 
 
Chia seeds 
Appendix 6 of the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/chiaappinfood.pdf). 
 
DHA-rich algal oil from Schizochitrium Sp.ONC-T18 
Chapter ‘3.1 Compositional equivalence’ and figure 3, Annex 3 and Annex 4 of the application dossier 
for notification (http://www.food.gov.uk/multimedia/pdfs/dhaoilont.pdf). 
 
Refined Buglossoides oil 
Chapter ‘B1 Identity of the source’ of the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/buglossoides-arvensis-application.pdf). 
 
Saskatoon berry (Amelanchier alnifolia) 
‘Appendix 1. Taxonomy of saskatoon berry and blueberry’ of the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/saskatoon.pdf). 
Box 14: The history of use in the application dossier for notification of Chia seeds 
 
Chapter ‘4.B History of use’ of the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/chiaappinfood.pdf). 
Box 15: Product specification of refined Buglossoides oil compared to that of Echium oil in 
the application dossier for notification 
 
Chapter ‘B2 Product specification’ of the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/buglossoides-arvensis-application.pdf). 
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4.2.4 Production process 
The application dossier should contain a specification of the preparation method, manufacture process, 
and chain for both the novel protein and the existing counterpart. A process diagram can be used to 
explain the process. Box 16 provides an example of the production process of refined Buglossoides oil 
compared to that of other edible oils in the application dossier for notification. 
 
 
 
4.2.5 Composition of product 
The novel protein should not contain significant levels of substances that are not present in the 
existing counterpart. If such substances are present, in general an application for notification will not 
be sufficient and an application for authorisation must be submitted. 
Compositional analyses should be reported for at least four batches of the novel protein and of the 
existing counterpart. The batches and composition must be representative for the product to be placed 
on the EU market. The analyses should be performed by accredited labs, preferably using accredited 
and validated methods of analysis. If available, official sampling methods should be used. Data has to 
include the average, standard deviation, and minimum and maximum limits of each of the substances. 
The results of analyses of the novel protein and of the existing counterpart should be compared by 
appropriate statistical methods. Copies of full laboratory reports and copies of the accreditation 
certificate of the labs should be added to the application dossier for notification in appendices. 
 
Provide data on the composition such as (note that not all parameters are applicable to all products): 
• Appearance; 
• Crude composition: moisture, total protein, total fat, ash, total carbohydrates, crude fibre; 
• Amino acid profile, fatty acid profile; 
• For isolated proteins: purity of the protein, solubility, pH 2% solution, amino acid composition, 
molecular mass, isoelectric point, absorption spectra, protease sensitivity, heat stability; 
• Micronutrients: vitamins (A, B1, B2, B3, B5, B6, B8, B9, B12, C, D, E, K1), minerals (Ca, Mg, P, Na, 
K, Zn, Fe, Cu, Mn, Cl), other relevant substances; 
• Inherent plant or animal toxins and/or antinutritional substances; 
• Heavy metals (Cd, Pb, As, F, Hg, Ni), pesticide residues, mycotoxins, other contaminants (like 
dioxins, dioxin-like PCBs, PCBs, PAHs, etc); 
• Substances used in processing (like solvents); 
• Substances formed during processing; 
• Microbiology: total bacteria (standard plate count), aerobic bacteria, Enterobacteriaceae, bacteria 
mentioned in Regulation (EC) 2073/2005, yeast and mould. 
 
Box 17 provides an example of the composition of refined Buglossoides oil compared to Echium oil in 
the application dossier for notification. 
 
 
Box 16: The description of the production process of refined Buglossoides oil compared to 
that of other edible oils in the application dossier for notification  
 
Chapter ‘B3 Preparation method’ of the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/buglossoides-arvensis-application.pdf). 
 
Box 17: The composition of refined Buglossoides oil compared to that of Echium oil in the 
application dossier for notification 
 
Chapter ‘B.5 Nutrient composition’ and ‘Appendix 1 - Summary of analytical results’ of the application 
dossier for notification (http://www.food.gov.uk/multimedia/pdfs/buglossoides-arvensis-
application.pdf). 
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 4.3 Nutritional value 
If the composition of the novel protein does not differ from its existing counterpart, it is unlikely that 
there will be significant differences in its nutritional value. Nevertheless, the applicant should consider 
this possibility and provide results of any relevant studies in the application dossier. The nutritional 
composition of the novel protein and the existing counterpart should be compared. Reference to the 
results of the composition of the novel protein and the existing protein can be made as described in 
paragraph 4.2.3. (Very) low intake levels compared to total dietary protein intake might imply that 
intake would not be nutritiously disadvantageous, without taking into consideration parameters like 
amino acid composition, mineral or ash levels in the product or digestibility of the protein. Box 18 
provides an example of general nutritional description of Chia seeds in the application dossier for 
notification. 
 
4.4 Metabolism 
If the composition of the product does not differ from its existing counterpart, it is unlikely that there 
will be significant differences in its metabolism. Nevertheless, the application should consider this 
possibility and provide results of any relevant studies. These might include the results of bioavailability 
studies and stability tests to show that the novel product does not degenerate during storage or use. 
4.4.1 Bioavailability 
The bioavailability of nutrients in the novel protein should be demonstrated. When the novel protein is 
consumed as intended within the proposed diet, the bioavailability of nutrients should not change 
when the existing counterpart is replaced by the novel protein. Data about the bioavailability from the 
existing counterpart can be used from literature, if the composition of the product or diet in which the 
novel protein is replaced does not change from its existing counterpart. Box 19 provides an example 
of bioavailability in the application dossier for notification. 
 
 
 
4.4.2 Stability of the product 
The compositional stability of the novel protein during the whole storage period has to be 
demonstrated. If data are available, you could show this with a literature research. Otherwise, you 
could perform storage experiments to show compositional stability. Box 20 provides an example of 
stability of the product in the application dossier for notification. 
 
 
 
Box 18: The general nutritional description in the application dossier for notification of 
Chia seeds 
 
Chapter ‘4.A General description’ of the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/chiaappinfood.pdf). 
Box 19: The bioavailability in the application dossier for notification of Chia seeds 
 
Chapter ‘5.A Bioavailability’ of the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/chiaappinfood.pdf). 
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4.5 Intended use 
The application dossier for notification should describe the uses of the existing counterpart and explain 
which of those are relevant to the novel protein. This may include use in food supplements, use as a 
food, and use as a food ingredient in a list of specified food categories. In general, new uses for a 
novel protein cannot be included in an application for notification, particularly if the use is likely to 
result in consumption of the protein by a wider range of the population or at higher levels, compared 
with the existing counterpart. For example, the novel protein cannot be assessed as ‘substantially 
equivalent’ if it is intended for use as an ingredient in foods and the existing counterpart is only 
consumed in the form of food supplements.  
 
The anticipated levels of intake should be specified in the dossier, based on the proposed level of 
substitution in the diet. Specific consumer groups at increased risk should be distinguished as well as 
differences in diet across the EU. Where the application covers use in food supplements, it should 
include information on the recommended dosage of the new protein and the existing counterpart. For 
further detailed information about the estimation of anticipated levels of intake, see paragraph 3.4.4. 
Box 21 provides examples of intended use of Chia seeds and refined Buglossoides oil in the application 
dossiers for notification. 
 
 
 
  
Box 20: The stability of the product in the application dossier for notification of Chia seeds 
 
Chapter ‘5.B Stability of the product’ of the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/chiaappinfood.pdf). 
Box 21: Intended use of Chia seeds and refined Buglossoides oil in the application dossiers 
for notification 
 
Chia seeds 
Chapter ‘6 Intended use’ of the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/chiaappinfood.pdf). 
 
Refined Buglossoides oil 
Chapter ‘E Intended use’ and ‘Table 2 – Intended food uses’ of the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/buglossoides-arvensis-application.pdf). 
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 4.6 Level of undesirable substances 
The application dossier should include an analysis of the potentially present undesirable substances, 
such as environmental contaminants, mycotoxins, allergens, naturally occurring toxins and anti-
nutrients, and pathogenic microorganisms. A detailed literature search could be performed to identify 
any undesirable substances that could be associated with the novel protein and its source. Box 22 
provides an example of such a literature study for refined Buglossoides oil. Analytical data should be 
provided for at least four representative batches of the novel protein and the existing counterpart to 
show that the levels of these substances are comparable between the novel protein and existing 
counterpart, and that levels are below maximum limits. If the potentially present undesirable 
substances are described in the composition of the novel protein and of the existing protein in 
paragraph 4.2.3, the substances can be referred to that chapter. Different chapters or paragraphs 
about chemical contaminants and heavy metals, microbiological content, and toxicity and safety 
studies can be included, as well as a detailed description of the Quality Management System proposed 
to use for the novel protein.  
 
 
 
4.6.1 Chemical contaminants and heavy metals 
In this paragraph the results of the analysis on external chemical contaminants and heavy metals 
should be provided. At least four batches of the novel protein and the existing counterpart should be 
analysed. For further information, see paragraph 4.6 and paragraph 3.4.1. Box 23 provides examples 
of chemical contaminants and heavy metals in the application dossier for notification. 
 
 
 
4.6.2 Microbiological content 
In this paragraph the results of the analysis on microbiological content should be provided. At least 
four batches of the novel protein and the existing counterpart should be analysed, taking into account, 
among others, relevant microbes and methods listed in Regulation (EC) No 2073/2005. For further 
information, see paragraph 4.6 and paragraph 3.4.7. Box 24 provides examples of the microbiological 
content in the application dossier for notification. 
 
 
Box 22: Literature study for the presence of undesirable substances in the application 
dossier for notification of refined Buglossoides oil 
 
Chapter ‘F Level of undesirable substances’ of the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/buglossoides-arvensis-application.pdf). 
 
Box 23: Chemical contaminants and heavy metals in the application dossier for notification 
of Chia seeds and of refined Buglossoides oil 
 
Chia seeds 
Chapter ‘13. Level of Undesirable Substances’ in the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/chiaappinvagrop.pdf) 
 
Refined Buglossoides oil 
Paragraph ‘F.3 External chemical contaminants’ and ‘Table 9 – Potential external contaminants’ of the 
application dossier for notification (http://www.food.gov.uk/multimedia/pdfs/buglossoides-arvensis-
application.pdf). 
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4.6.3 Toxicity and safety studies 
In this paragraph the results of the analysis on toxicity and allergenicity should be provided. No 
toxicological tests will be needed, if full substantial equivalence can be established based on 
compositional comparison. For further information, see paragraph 4.6 and paragraph 3.4.8. Box 25 
provides examples of the toxicological content in the application dossier for notification. 
 
 
 
4.6.4 Quality and Hygiene system 
Describe the Quality Management Systems (e.g. HACCP, GMP, ISO, GlobalGAP) you propose to use for 
the novel protein. This should include a description of the HACCP scheme which is used to identify and 
control microbiological hazards. This HACCP scheme should include the stages of storage and 
transport. For further information, see paragraph 3.4.2.  
4.7 Other relevant data 
In the application dossier, the results from a literature survey about any other relevant data on the 
novel protein can be provided, including the reports of any safety studies. 
 
If necessary, the application dossier for notification should also include a proposal for labelling, to 
demonstrate that consumers and other users will be adequately informed of the nature of the novel 
protein, its intended use, and any restrictions that may need to be respected. Requirements for 
labelling of the novel protein are additional to the general EU requirements on food labelling. Where 
necessary, labelling of novel protein may mention:  
 
• Characteristics - composition, nutritional value, intended use;  
• Materials which may affect the health of some individuals, such as allergy; 
• Materials that give rise to ethical concerns. 
Box 24: Microbiological content in the application dossier for notification of Chia seeds and 
of refined Buglossoides oil 
 
Chia seeds 
Chapter ‘14. Microbiological Information of the Chia Seed’ in the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/chiaappinvagrop.pdf) 
 
Refined Buglossoides oil 
Paragraph ‘F.2 Microbiology’ and ‘Table 12 – Microbiological tests’ of the application dossier for 
notification (http://www.food.gov.uk/multimedia/pdfs/buglossoides-arvensis-application.pdf). 
 
Box 25: Toxicological content in the application dossiers for notification of Chia seeds and 
of refined Buglossoides oil 
 
Chia seeds 
‘Chapter 15. Allergy’ of the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/chiaappinvagrop.pdf). 
 
Refined Buglossoides oil 
Paragraph ‘F.1 Inherent Substances’ and ‘Table 10 – Dioxins and dioxin-like PCBs’ and ‘Table 11 -
Polycyclic aromatic hydrocarbons (PAHs)’ of the application dossier for notification 
f f f  
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The application dossier should include details of any monitoring that will be undertaken to provide on-
going assurance that the product is of appropriate quality with regard to its composition and the 
presence of undesirable substances. Box 26 provides examples of the description of the other relevant 
data for chia seeds and refined Buglossoides oil. 
 
 
 
4.8 Evaluation and conclusion by the applicant 
The applicant has to evaluate all the information provided in the former chapters and conclude on the 
substantial equivalence of the novel protein with the existing counterpart. The evaluation and the 
conclusion drawn can only be based on information presented in the application dossier. Box 27 
provides examples of the conclusion in the application dossier for notification. 
 
 
 
4.9 References and appendices 
The applicant has to list all references in the text in a reference list at the end of the main text in the 
application dossier. 
 
To improve readability of the main text in the application dossier, it is advised to put the most 
important information in the main text and present detailed data in tables and figures in appendices. 
Box 28 provides examples of the references and appendices for chia seeds and refined Buglossoides 
oil.  
 
Finalise a notification dossier by adding a summary. 
 
Box 26: Other relevant data in the application dossier for notification of Chia seeds and of 
refined Buglossoides oil 
 
Chia seeds 
Chapter ‘8 Labelling’ and chapter ‘17. OTHER RELEVANT DATA’ of the application dossier for 
notification (http://www.food.gov.uk/multimedia/pdfs/chiaappinvagrop.pdf). 
 
Refined Buglossoides oil 
Chapter ‘G Other relevant data’ of the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/buglossoides-arvensis-application.pdf). 
Box 27: Conclusion in the application dossier for notification of Chia seeds and of refined 
Buglossoides oil 
 
Chia seeds 
Chapter ‘16. CONCLUSION’ of the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/chiaappinvagrop.pdf). 
 
Refined Buglossoides oil 
Chapter ‘A.1 Basis of application’ of the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/buglossoides-arvensis-application.pdf). 
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Box 28: References and appendices in the application dossier for notification of Chia seeds 
and of refined Buglossoides oil 
 
Chia seeds 
Chapter ‘18. REFERENCES’ and chapter ‘19. APPENDIX’ of the application dossier for notification 
(http://www.food.gov.uk/multimedia/pdfs/chiaappinvagrop.pdf). 
 
Refined Buglossoides oil 
Chapter ‘References’ on p24 and the appendices starting on p28 of the application dossier for 
notification (http://www.food.gov.uk/multimedia/pdfs/buglossoides-arvensis-application.pdf). 
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  Overview of competent Annex 1
 authorities in EU members 
 states 
EU Member 
State 
Insti-tu- 
tiona 
Name Link to the novel food page information 
Austria  Österreichische Agentur für Gesundheit und 
Ernährungssicherheit GmbH (AGES) 
http://www.ages.at/ages/ernaehrungssicherhei
t/neuartige-lebensmittel 
  Bundesministerium für Gesundheit (BMG) http://www.bmg.gv.at/home/Schwerpunkte/Ve
rbraucherInnengesundheit/Lebensmittel/Neuart
ige_Lebensmittel/ 
Belgium  Department for Foods, Animal Foods and Other 
Consumption Products (DG for Animals, Plants 
and Foodstuffs) 
http://www.health.belgium.be/eportal/foodsafe
ty/foodstuffs/novelfoods/%3Ffodnlang%3Dnl 
  Hoge Gezondheidsraad  
  Federal public Service – Health, Food Chain 
Safety and Environment (FSP-HFCSE) 
 
  Conseil Supérieur de la Santé (CSS)  
Denmark  Danish Veterinary and Food Administration http://www.foedevarestyrelsen.dk/english/Abo
utus/Organization/Head_Office/Pages/default.a
spx 
  Ministeriet for Fødevarer, Landbrug og Fiskeri 
(MfFLoF) 
 
Finland  Coordination authority in Finland is Food Safety 
Authority Evira (Evira) 
http://www.evira.fi/portal/en/food/manufacture
+and+sales/novel+foods/novel+food+applicati
ons/ 
  Novel Food Board (NFB)  
France  
 
French Agency for Food, Environmental and 
Occupational Health & Safety (ANSES) 
http://www.anses.fr/en/content/novel-foods-
and-food-ingredients 
  Direction Générale de la Concurrence, de la 
consummation et de la répression des Fraudes 
(DGCCRF) 
 
  Agence française de sécurité sanitaire des 
alimentes (AFFSA) 
 
Germany  Bundesinstitut für Risikobewertung / Federal 
Institute for Risk Assessment (BfR) 
http://www.bfr.bund.de/de/novel_foods-
215.html 
  Bundesinstitut für gesundheitlichen 
Verbrachersschutz und Veterinärmedizin (BgVV) 
 
  Bundesamt für Verbrachersschutz und 
Lebensmittelsicherheit (BVL) 
 
Ireland  Food Safety Authority of 
Ireland (FSAI) 
http://www.fsai.ie/science_health/novel_food_
applications/safety_assessments.html  
    
Netherlands AU Ministerie van Volksgezondheid, Welzijn en 
Sport (VWS)/ Ministry of Public Health, Welfare 
and Sport 
 
 AB The Medicines Evaluation Board (CBG MEB) http://www.cbg-meb.nl/CBG/en/novel-
foods/actueel/default.htm 
    
Poland  Instytut Roślin I Przetworów Zielarkich (IRPZ)  
  Instytut Żywności I Żywienia (IZIZ)  
  Państwowa Inspekcja Sanitarna http://gis.gov.pl/dep/?lang=en&dep=14&id=29 
Spain  Agencia Española de Seguridad Alimentaria y 
Nutrición. 
Ministry of Agriculture, Fisheries and Food. D.G 
IA y (AESAN) 
http://www.aesan.msc.es/en/AESAN/web/cade
na_alimentaria/subseccion/nuevos_alimentos_n
uevos_ingredientes.shtml 
Sweden  National Food Administration (NFA)  
United Kingdom  Advisory Committee on Novel Foods and 
Processes (ACNFP) 
http://acnfp.food.gov.uk/assess/ 
  Food Safety Agency (FSA)  
    
a AU = Authority, AB = Assessment body, and AB+AU = Authority + Assessment body 
b (BNV) Bureau Nieuwe Voedingsmiddelen or Novel Food Unit is part of CBG-MED   
LEI 14-075 | 49 
  Fees to be paid to authority for Annex 2
 assessment Novel Food 
EU Member State Authority Authorisation Notification 
Belgium (1998) DG for Animals, Plants and 
Foodstuffs / 
Superior Health Council 
€3,718.50 €1,239.50 
Germany (…) BfR €2,556 and €5,113. €2,556 - €5,113 
Netherlands (2008) CBG MEB €25,838 €2,086 
Finland EVIRA / NFB Evira: €2,463 for processing dossier 
Novel Food Board: €2,700 – €25,000 
(assessment: depending on the 
complexity and work to be done) 
Evira: €985 for processing 
dossier 
Novel Food Board: €700. 
Total: €1,685 
United Kingdom (2013) ACNFP €4,650 (₤4,000) €2,005 (₤1,725) 
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